Procedimientos, técnicas y comunicaciones en Urología, Geriatría, Anestesia y Endocrinología.
Contenido principal del artículo
Resumen
En 1995, se diagnosticaron cerca de 244,000 casos nuevos de cáncer de la próstata en los Estados Unidos. La mortalidad por esta causa llegó a cerca de 40,000 pacientes. El riesgo de padecer cáncer de próstata es en la población general de 8%.' La incidencia de sospecha de cáncer de próstata mediante tacto rectal y APE es de 10-15% en hombres de 50 años, el cual aumenta hasta 40% a la edad de 80 años.
Detalles del artículo
Sección
Cómo citar
Referencias
Bazinet M. Vallue of sytematic transítion zone biopsies in the early detection of prestare cancer. J Urol 1996;155:605-6.
Dalkin, Ahmann, Kopp. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. The Journal of Urology 1993;150: 1837-1839.
Rosen MA. lmpact of prostate-specific antigen screening on the natural history of prestare cáncer. Urology 1995;46:757-68.
Riehman, Rhodes, Cook, Grose, Bruskewitz. Annlysis of variation in prostate specific antigen values. Urology 1993;42(4):807-812.
Gilligand FO y Key CD. Male genital cancer. Cancer 1995;75: 295-315.
Smith DS y Catalana WJ. The nature of prostate cancer detected through prostate specific antigen based screening, J Urol 1994; 152:1732-36.
Wang WC, Valenzuela LA. Murphy GP. Purification of a human prostate specific antigen. Invest Urol 1979;17:158-63.
Partin AW, Osterling JE. The clinical usefulness of prostate specific antigen update 1994. A. W. the Joumal of Urology 1994;152: 1358-1368.
Kutiyama M, Wang MC, Papsidero LD. Killian Cs, Shimano T, Valenzuela L, Nishiura. T, Murphy GP y Chu TM. Quatitation of prostate specific antigen in serum by sensitive enzyme immunoassay. Cancer Res l 980;40:4658.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, y Redwin E. Prostatic-speciflc antigen and prostatic AA, A serum marker for adenocarcinoma of the prestare. New Engl J Med 1987;317:909.
Osterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prestare. J Urol 1991;145:907-923.
Charles B. Brendler MD. Prostate specific antige: Its role in the diagnosis and stagging of prostate cancer. Controversies in the management of pros tate. Cancer l990;Part 4:4-11.
Christensson A, Björk T. Nilsson O, Dahlen U, Matikaien T, Cockett ATK, Abrahamsson P y Lilja H. Serum prostate specific antigen complexed to alfa 1-antichymotrypsin as an indicator of prestare cancer. J Urol 1993;150: 100-105.
Osterling MD, Lilja MD. Prostate specific antigen: The value of molecular forms and age specific reference ranges. The Michigan Prostate Center and the University of Michigan Ann Arbor Michigan, and Department of Clinical Chemistry Lund University Malmo. Sweeden, 1994.
Stamey TA. Second stanford conference on international standarization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology 1995;45: 173-83.
Osterling JE, Lilja H. Wag TJ et al. Molecular forms of prostate specific antigen and the human kallikrein gene family: A new era. Urology 1995;45:729-44.
Partin AW, Osterling JE. The clinical usefulness of prostate specific antigen update 1994. J Urol 1994;152:1358-1368.
Haab F, Meulemans A, Boccon-Gibod L, Dauge MC, Delmas V·,Hennequin C, y Benbunan D. Efect of radition therapy after radical prestatectomy on serurn prostate-specific antigen measured by an ultrasensitive assay, Urology 1995;45:1022-27.
Brawer M. Laboratory studies for the detection of carcinoma of the prostate. The Urol Clin North Am 1990:7:759-68.
Osterling JE, Jacobsen SJ, Chute CG, Guess HA, Dirman Cj, Panser LA, Lieber MM. Serum prostate-specific antigen in community-based population of healthy men: establishment of age-specific reference ranges, JAMA 1993;270:860-64.
Resgl A. Pointer J, Hominger W, Ennemosr O, Strasser H, Kolcker H y Bartsch G. Comparation of different prostate-specific antigen cutpoints for early detection of prostate cancer. Results of a large screening study. Urology 1995;45:662-65.
Bangma CH, Kranse P, Blijmberg BG, Schroder FH. The value of screening test in the detection of prostate cancer. Part II: Retrospective analysis of free total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology l995;46:779-84.
Leventhal, Rozanski, Morey, Rholl. The effects of exercise and activity of serum prostate-specific antigen levels. The Journal of Urology 1993; 150:893-894.
Simark, Maderebacher, Zhang, Male. The impact of ejaculation on serum prostate-specific antigen. The Journal of Urology 1993;150:891-897.
Osterling, Rise, Glenski, Bergetralh. Effect of cystoscopy, prostate biopsy and transurethral resection of prostate on serum prostate specific antigen concentration. Urology 1993;42(3):276-282.
Kojirna, Troncoso, Babaian. Use of prostate specific antigen and tumor volumes in predicting needle biopsy grading error. Urology 1995;45(5):807-812.
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Conner WH. Prostate specific antigen density a means of distinguishing bening prostatic hyperirophy and prostate cancer. J Urol: Part 2. t992;147:815-17.
Carter HB, Pearson ID, Metter EJ, Brant LJ, Chan DW. Andres R, Fozard IF, Waish PC. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2213-20.
Optemberg SA, Thompson IM. Econnmics of screening for carcinoma of the prostate. The Urol Clin North Am 1990:7:719-35.
Denis LJ: Prostate cancer screening and prevention: “Realities and hope". Urology 1995;(Suppl):46:56-61.
Lange T. Prostate-specific antigen for staging prior to surgery and early detection of recurrence after surgery. The Urol Clin North Am l990;7:813-17.
Leutwyler K. The price of prevention. Scientific Am. April 1995:98-103.
Humphrey PA, Keetch DW, Smith DS, Shepeherd DL, Catriona WI. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate-specific antigen based screening. J Urol 1996 155:816-820.
Lemer SE, Seay TM, Blute MW, Bergsiralh BJ, Barret D, Zincke H. Prostate specific antigen detectred prostate cancer (clinical stage TIC) an interim analysi.s. J Urol 1996;155:821-826.
Catalona WJ. Screening for prostate cancer: enthusiasm. Urology 1993;42(2): 113-115.
Romell FM, Augusta VE, Brest in JA, Huffimagle HW. Pohl CA, Sierber PR, Stahi CA. The use of prostate specific antigen density in the diagnosis of prosiatic cancer in a community based urology practice. J Urol 1993; 151:88-92.
Caffey DS. Prostate cancer, an overview of an increasing dilemma. Cancer Suppl 1993;71:880-86.
Terrie, Haney, Johnstone, MxNeai. Stamey. Prediction of prostate cancer volumes using prostate specific antigen levels, transrectal ultrasound and sistematic sextant biopsies. Urology 1995;45(1):75-80.
Scaletscky R, Koch O, Smith JA Jr et al. Tumor volumen and stage in carcinoma of prostate detected by elevations in prostate specific antigen. J Urol 1994;152: 129- 131.
Carter, Pearson, Wachaww, Metter, Chan, Guess, Walsh. Prostate specific antigen variability in men without prostate cancer: effect of sampling interval on prostate specific antigen velocity. Urology 1995; 45(4):591-596.